Gen Li is president of Phesi. He can be reached at gen.li@phesi.com.
New data shows that China and the US dominate breast cancer clinical trial expertise while lower-income countries remain under-used. Dr Gen Li, founder and president of Phesi, analyzes the numbers and discusses how smart use of AI and clinical data can address the gap.
Gen Li, founder and president of Phesi, discusses how the industry is considering GLP-1s from a more holistic approach.
Gen Li, founder and president of Phesi, discusses how the rise of GLP-1 medications is impacting how various diseases are treated beyond the ones the medications are specifically designed to treat.
A new study of hundreds of thousands of clinical trial records reveals that the overall length of a trial is directly related to how long it takes to activate the study sites - and that most companies are wasting precious weeks and even months in activation. Here's how to improve your performance.
Not long ago the average pharma development organization spent $100 to $200 million a year. It consisted of about 100 people working on only a half dozen compounds. Its leaders typically knew all their employees by name. There was a good deal of visibility within the organization: Managers could see from top to bottom and could make decisions aided by nothing but their own brains.
Published: December 12th 2008 | Updated:
Published: October 31st 2003 | Updated:
